Search

Alla Laufer

from Brooklyn, NY
Age ~66

Alla Laufer Phones & Addresses

  • 2169 West St, Brooklyn, NY 11223
  • Bronx, NY

Work

Company: Ortec int 1997 to 2008 Position: Scientist 2

Education

School / High School: Manhattan College 1995 to 1999

Industries

Biotechnology

Resumes

Resumes

Alla Laufer Photo 1

Scientist 2

View page
Location:
New York, NY
Industry:
Biotechnology
Work:
Ortec Int 1997 - 2008
Scientist 2

Ortec 1997 - 2008
Scientist 2
Education:
Manhattan College 1995 - 1999

Publications

Us Patents

Processes For Making Cryopreserved Composite Living Constructs And Products Resulting Therefrom

View page
US Patent:
20020123809, Sep 5, 2002
Filed:
Dec 26, 2001
Appl. No.:
10/032929
Inventors:
Hsin-Chien Tai - Hackensack NJ, US
Alla Laufer - Brooklyn NY, US
Ying Song - Franklin Park NJ, US
Nitya Ray - East Hanover NJ, US
International Classification:
A61F002/02
US Classification:
623/023720, 435/374000
Abstract:
Processes are described for making a cryopreserved Composite Living Construct (CCLC) as well as a corresponding thawed and rinsed CCLC, comprised of separated layers of cultured fibroblasts and cultured keratinocytes, wherein the percent of cells that are viable, i.e., the cell viability, of such CCLC is at least about70 %. The viable cell density in the CCLC is at least about 50% of that before cryopreservation. The storage stability of the CCLC is at least about 12 months. Additionally, the metabolic activity of thawed and rinsed CCLC is at least about 50% of the Composite Living Construct (CLC) before cryopreservation. The structural integrity of CCLC is substantially the same as the CLC before cryopreservation. The process for making the CCLC comprises the steps of: providing a collagen substrate comprised of a collagen sponge layer and a nonporous to cells, semipermeable collagen layer; seeding and culturing, in the presence of a cell growth medium, fibroblasts on and within the collagen sponge layer and keratinocytes on the nonporous to cells, semipermeable collagen layer, thereby providing a CLC; equilibrating the CLC, according to a defined equilibration program with a cryoprotectant solution comprising at least chondroitin sulfate and dimethylsulfoxide; lowering the temperature, according to a programmed rate, to about -90 C.; and storing the CCLC at about -150 C. or lower. The process for preparing the CCLC to treat wounds in humans and in animals additionally comprises programmed thawing as well as a rinsing sequence to substantially remove the cryoprotectants.

Processes For Making Cryopreserved Composite Living Constructs And Products Resulting Therefrom

View page
US Patent:
20040053409, Mar 18, 2004
Filed:
Aug 15, 2003
Appl. No.:
10/641655
Inventors:
Hsin-Chien Tai - Hackensack NJ, US
Alla Laufer - Brooklyn NY, US
Ying Song - Franklin Park NJ, US
Nitya Ray - East Hanover NJ, US
Assignee:
Ortec International, Inc. - New York NY
International Classification:
C12N005/08
US Classification:
435/374000, 435/397000
Abstract:
Processes are described for making a cryopreserved Composite Living Construct (CCLC) as well as a corresponding thawed and rinsed CCLC, comprised of separated layers of cultured fibroblasts and cultured keratinocytes, wherein the percent of cells that are viable, i.e., the cell viability, of such CCLC is at least about 70%. The viable cell density in the CCLC is at least about 50% of that before cryopreservation. The storage stability of the CCLC is at least about 12 months. Additionally, the metabolic activity of thawed and rinsed CCLC is at least about 50% of the Composite Living Construct (CLC) before cryopreservation. The structural integrity of CCLC is substantially the same as the CLC before cryopreservation. The process for making the CCLC comprises the steps of: providing a collagen substrate comprised of a collagen sponge layer and a nonporous to cells, semipermeable collagen layer; seeding and culturing, in the presence of a cell growth medium, fibroblasts on and within the collagen sponge layer and keratinocytes on the nonporous to cells, semipermeable collagen layer, thereby providing a CLC; equilibrating the CLC, according to a defined equilibration program with a cryoprotectant solution comprising at least chondroitin sulfate and dimethylsulfoxide; lowering the temperature, according to a programmed rate, to about -90 C.; and storing the CCLC at about -150 C. or lower. The process for preparing the CCLC to treat wounds in humans and in animals additionally comprises programmed thawing as well as a rinsing sequence to substantially remove the cryoprotectants.
Alla Laufer from Brooklyn, NY, age ~66 Get Report